Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > BUSINESS
BUSINESS
- Ono Takes Part in University of California Drug Discovery Consortium
March 29, 2021
- Takeda Files Dengue Vaccine Candidate in Europe
March 29, 2021
- EMA Accepts Regulatory Filing of Enfortumab Vedotin: Astellas/Seagen
March 29, 2021
- Astellas Sees Growth Potential for “Rx+” as Future Bread-and-Butter Biz: EVP
March 26, 2021
- Boehringer’s Japan Sales Up 5.4% in 2020 as Ofev, Jardiance Fare Well
March 25, 2021
- Kissei Launches PIII Study of Oncolytic Viral Therapy for Bladder Cancer in Japan
March 25, 2021
- Chugai Earns Japan Nod for Blood-Based Genomic Profiling Test
March 24, 2021
- Sumitomo Dainippon Aims to Overcome Latuda Patent Cliff with Sumitovant Products: CSO
March 24, 2021
- Rohto Acquires Olympus’ Regenerative Medicine Unit
March 24, 2021
- Kowa, Kitasato Institute Team Up for Research of Infectious Disease Meds; Cepharanthine for COVID-19
March 24, 2021
- Shionogi Partner BioAge Begins US PII Study for COVID-19 Drug
March 24, 2021
- Taiho Files Antiemetic Fosnetupitant for Japan Approval
March 24, 2021
- Taisho Seeks Japan Approval for Anti-TNFα Nanobody Ozoralizumab
March 23, 2021
- Otsuka Files Tolvaptan Prodrug OPC-61815 in Japan
March 23, 2021
- Daiichi Sankyo Begins Japan PI/II for mRNA COVID-19 Vaccine
March 23, 2021
- KM Biologics Kicks Off Japan PI/II for COVID-19 Vaccine
March 23, 2021
- Eisai Starts Construction of New Injectable/Research Building in Gifu Pref.
March 23, 2021
- Japan Approves 3rd CAR-T Cell Therapy, Celgene’s Breyanzi
March 23, 2021
- ASKA Aims for 70 Billion Yen Sales by FY2025 on Growth of OB-GYN, Thyroid Spaces: New Biz Plan
March 23, 2021
- Takecab OD Tablet Filed in Japan: Takeda/Otsuka
March 23, 2021
ページ
Japan’s pharmaceutical industry is undergoing a structural shift in its workforce, with the role of sales reps shrinking while production…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…